Liu Xinshu, Zhang Meifen
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. Email:
Zhonghua Yan Ke Za Zhi. 2015 Feb;51(2):151-4.
Macular edema represents a major cause of visual loss in uveitis and its adequate management is crucial for the maintenance of useful vision in patients with uveitis. Corticosteroid is the first choice for UME treatment.Long term and sustained release implantation is the newest administration for medical therapy. The immunosuppressant such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil can be used specially for chronic and intractable UME. Moreover, these years, some newly developed biological agents, for example, anti-VEGF, interferon-α, anti-TNF and acetazolamide will provide new options for UME pharmacotherapy.
黄斑水肿是葡萄膜炎导致视力丧失的主要原因，对其进行充分治疗对于维持葡萄膜炎患者的有效视力至关重要。皮质类固醇是治疗葡萄膜炎性黄斑水肿的首选药物。长效缓释植入是药物治疗的最新给药方式。免疫抑制剂如环孢素、甲氨蝶呤、硫唑嘌呤和霉酚酸酯可专门用于治疗慢性和难治性葡萄膜炎性黄斑水肿。此外，近年来，一些新开发的生物制剂，如抗血管内皮生长因子（anti-VEGF）、干扰素-α、抗肿瘤坏死因子（anti-TNF）和乙酰唑胺，将为葡萄膜炎性黄斑水肿的药物治疗提供新的选择。
